Skip to content

Comparison of Dagdhasnukkandaadi Lepa and Pathyadi Lepa Along with Panchatikta Ghrita Guggulu Vati for Treating Eczema (Atopic Dermatitis)

A Single Blinded Randomised Comparitive Clinical Study To Evaluate The EFFICACY Of DAGDHASNURKKANDAADI LEPA and PATHYADI LEPA Along with PANCHATIKTA GHRITA GUGGULU VATI in the Management Of VICHARCHIKA KUSHTA WITH SPECIAL REFERENCE TO ECZEMA (ATOPIC DERMATITIS) - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112956
Enrollment
40
Registered
2026-06-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

None listed

Sponsors

Dr Rudresh Jagdish Joshi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects presenting with clinical features of Vicharchika and Eczema Atopic dermititis as per Ayurvedic and Contemporary science respectively Subjects between the age group of 16 to 60 years irrespective of gender and religion Itchy skin rash or history of itch or rubbing and at least three of the following should be present History of involvement of skin creases or cheeks if more than 4 years History of atopic disease asthma, hay fever or in a first degree relative if more than 4 years Visible flexural eczema on cheeks, forehead, outer limbs if 4 years Onset in first 2 years of life Dry skin Xeroderma

Exclusion criteria

Exclusion criteria: Subjects below the age group of 16 years and above the age group of 60 years. Subjects showing acute signs and symptoms indicating fatal consequences. Participants with impaired renal, hepatic, and cardiac function. Subjects with Known case of Hypertension/Hypotension, diabetes mellitus, hypothyroidism, hyperthyroidism or any Known major systemic disorders. Recent history of Myocardial Infraction, Stroke. Pregnant and lactating mother. Subjects with evidence of any other illness which may interrupt the treatment

Design outcomes

Primary

MeasureTime frame
Reduced skin lession Reduced burning sensation Reduced itching and pain Reduced local secretions from skin Reduced drynessTimepoint: 4 weeks

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDr I B Kotturshetti

RGESAMCH Ron

dranandadi7929@gmail.com9448337929

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026